DYRK1A,

related kinases

& human disease conference

Saint-Malo, France
March 23 - 27, 2021

General information

General presentation

All major physiological phenomena are regulated by protein phosphorylation which is catalysed by protein kinases. Many diseases are associated with abnormal phosphorylation. Consequently, the last four decades have seen considerable efforts in the study of function and regulation of protein kinases in essentially all aspects of biology. In parallel, pharmacological inhibitors of kinases have become a major R&D area for the pharmaceutical industry in its search for new therapies. As of early 2020, 49 kinase inhibitors have reached the pharmaceutical market.

DYRKs (‘dual specificity, tyrosine phosphorylation regulated kinase 1’) (DYRK1A, 1B, 2, 3, 4) play key roles in mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle, differentiation, endocytosis, neuronal development and functions, synaptic plasticity, folate and methionine metabolism. Inhibition of DYRKs may find applications in Down syndrome, Alzheimer’s disease and tauopathies, Parkinson’s disease, CDKL5 Deficiency Disorder diabetes, osteoarthritis, viral infections and various cancers. The closely related CLKs (‘cdc2-like kinases) (CLK1, 2, 3, 4) also play essential functions in Alzheimer’s disease and tauopathies, alternative splicing, various viral infections, cancers, body temperature sensing. DYRK and CLK orthologs are found in plants, yeast and unicellular parasites.

 

The conference will focus on DYRK1A and related kinases, including structural, regulatory and functional aspects, substrates and interactors, functions at cell and organism levels as well as development and potential therapeutic use of selective pharmacological inhibitors.

Location

Palais du Grand Large, St Malo, Bretagne, France

www.pgl-congres.com

 

Scientific information

 
Organizers

Laurent MEIJER

Perha Pharmaceuthicals,

Roscoff, France

Masatoshi HAGIWARA

Department of Anatomy

& Developmental Biology,

Graduate School of Medicine,

Kyoto University, Kyoto, Japan

Peter P. DE DEYN

Department of Neurology,

General Hospital Middelheim and Institute Born-Bunge University of Antwerp,

Antwerpen, Belgium

Contact

Mariona ARBONES, Barcelona, Spain

          Control of neuron numbers by DYRK1A: lessons from mouse models

 

Walter BECKER, Aachen, Germany

          DYRK1B – a cancer drug target?

 

Thierry BESSON, Rouen, France

          Novel DYRKs/CLKs inhibitors

 

Mara DIERSSEN, Barcelona, Spain

          Clinical trials with EGCG, PERSEUS trial

 

Peter DE DEYN, Antwerpen, Belgium

          Down syndrome, Alzheimer’s disease & DYRK1A

 

Susana DE LA LUNA, Barcelona, Spain

          DYRK1A & DNA damage

 

Masatoshi HAGIWARA, Kyoto, Japan

          Development of inhibitors of CLK1 and DYRK1A, and their clinical applications

 

Yann HERAULT, Strasbourg, France

          The role of DYRK1A dosage in Down syndrome deficits

 

Florian HEYD, Berlin, Germany

          CLK in body temperature cycles

 

Nathalie JANEL, Paris, France

          DYRK1A interactants, a link between Down's syndrome and Alzheimer’s disease

Stefan KNAPP, Frankfurt, Germany

          Selective targeting of kinases regulation RNA splicing

 

Akiko KOBAYASHI, Kyoto, Japan

          Neuroprotection through suppression of inflammation by DYRK inhibitors

 

Conrad KUNICK, Braunschweig, Germany

          New DYRK1B inhibitors

 

Laurent MEIJER, Roscoff, France

          Leucettinibs, a second-generation family of DYRKs/CLKs inhibitors: from natural products to clinical

          applications

Lenka MUNOZ, Sydney, Australia

          Phosphoproteomic screen in cells upon DYRK1A inhibition: identification of new DYRK1A down-stream

          substrates

 

William M. OLD, Boulder & Aurora, USA

          Revealing new functions of DYRK1A through interactome and substrate profiling

 

Sang Ki PARK, Pohang, Korea

          Sequential phosphorylation of NDEL1 by the DYRK2-GSK3β complex is critical for neuronal

          morphogenesis

 

Lucas PELKMANS, Zurich, Switzerland

          Kinase-controlled phase transition of membrane-less organelles in mitosis

 

Amélie PITON, Illkirch, France

          DYRK1A, a gene frequently mutated in intellectual disability

Randall J. ROPER, Indianapolis, USA

          DYRK1A and skeletal deficits associated with Down syndrome

 

Andrew F. STEWART, New York, USA

          DYRK1A inhibitors for beta cell proliferation to treat diabetes

I'm busy working on my blog posts. Watch this space!

Please reload

Invited speakers (tentative titles)
Program

The final program will be available in February 2021.

Abstract submission

Organization: Arial 11, 1 page maximum, title (bold), authors (underline presenting author), addresse-mail contactabstract, 1-3 compact references, (funding). Save under ‘yourname.doc’ or ‘yourname.docx’.

Submit abstract as an attached Word document, through the Conference e-mail address                                   (dyrk-conference@perha-pharma.com), with your name as ‘subject’.

Abstract submission deadline: January 31, 2021.

Instructions for speakers

There will be no poster sessions. We will try to have as many people as possible, especially students and post-docs, presenting their results. Besides invited speakers, submitted abstracts will be selected for long (15 min) or short (5 min) oral presentations (+ 5 min discussion).

Call for authors

We plan to put together an open-access e-book collating articles on the conference topic. It will be published by Frontiers in Neurology (www.frontiersin.org). Contribution to this e-book will be open to everyone, whether attending or not to the conference. The plan is to have the final e-book ready by the opening of the conference. Please consider this opportunity. More information will be sent to the DYRKs/CLKs community in the coming months.

I'm busy working on my blog posts. Watch this space!

Please reload

saint-malo2.jpg

Travel

Travel grants for young researchers

The « Fondation Vaincre Alzheimer » is open to receive travel grant applications from young researchers.  Do not hesitate to submit your application at: https://www.vaincrealzheimer.org/espace-chercheur-bourse-voyage/

Getting to Saint-Malo

The easiest: Fast train (TGV) from Paris-Montparnasse train station.

Please consult our information for international access here.

Saint-Malo & Brittany

Tourism office: www.saint-malo-tourisme.com

Saint-Malo city hall: www.ville-saint-malo.fr

Registration

& Accommodation

Registration
Important dates

Very early bird registration deadline: November 30, 2020.

Early bird registration deadline: January 6, 2021.

Late registration: January 7, 2017 up to February 15, 2021.

Start of the conference: March 23, 2021 at 17:00.

End of the conference: March 27, 2021 at 12:00.

Registration cost

Registration comprises access to all conferences, program, coffee/tea breaks and lunches.

 

Very early bird registration deadline:

Industry: 600 €                        Academy: 500 €                      PhD Students*: 300 €.

Early bird registration deadline:

Industry: 800 €                        Academy: 600 €                      PhD Students*: 400 €.

Late registration:

Industry: 1000 €                      Academy: 700 €.                     PhD Students*: 500 €.

                                                                                                 * Photocopy of student card required

Nota Bene. In case a pandemic crisis prevents you to join the conference, your registration will be fully reimbursed (up to Februray 23rd).

Accommodation

Please consult our list of accommodation here.

 
 
 

Sponsorship

& Exhibitions

Click on the logo to access the site.

perha-pharma.jpg
Vaincre Alzheimer.png
Campus de la Mer.png
J.Lejeune logo.png
T21RS ok.png

© 2020 Perha Pharmaceuticals

Photo credits : OceanwideImages.com, Corinne Queme, Karin Maritz